727 FinancePANews October 21 news, according to an official OpenAI announcement, OpenAI has acquired Orchestra Bio, a drug R&D collaboration platform. The platform helps biopharmaceutical teams coordinate complex drug development processes, allowing scientists and project leads to delegate the monitoring and tracking of research and trials to AI agents. OpenAI stated that it will integrate Orchestra's team and technology with Rosalind, its life sciences research AI model and tool, to help new therapies reach patients faster.
OpenAI acquires drug R&D collaboration platform Orchestra Bio
Related news
Financing Weekly | Kalshi completes $1 billion Series G funding, led by Sequoia Capital and Wellington Management.
Kalshi completed a $1 billion Series G funding round, reaching a post-money valuation of $40 billion, nearly double its $22 billion valuation in May this year;...